Update on Novel Therapeutics for Primary CNS Lymphoma
Primary central nervous system lymphoma (PCNSL) is a rare lymphoma isolated to the central nervous system or vitreoretinal space. Standard treatment consists of cytotoxic methotrexate-based chemotherapy, with or without radiation. Despite high rates of response, relapse is common, highlighting the n...
Main Authors: | Lauren R. Schaff, Christian Grommes |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/21/5372 |
Similar Items
-
PRIMARY CNS LYMPHOMA MIMICKING TUBERCULOSIS INFECTION - A CASE REPORT
by: Hassan Mumtaz, et al.
Published: (2021-12-01) -
Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study
by: Lauren R. Schaff, et al.
Published: (2022-01-01) -
Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis
by: Sabine Seidel, et al.
Published: (2023-02-01) -
Sarcoidosis in Close Family Members and Susceptibility to High Grade B-Cell Lymphoma: A Case Report Study
by: Hana Magrouni, et al.
Published: (2022-11-01) -
Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
by: Hans-Georg Wirsching, et al.
Published: (2021-06-01)